NCT06999902 - Double-blind, Randomized Trial of PRAX-628 in Adults With Focal Seizures to Evaluate Efficacy and Safety (POWER1) | Biotech Hunter

Enrollment

230

Participants

Timeline

Start Date

December 11, 2024

Primary Completion Date

November 24, 2025

Study Completion Date

December 8, 2025

Conditions

Focal Seizure

Interventions

DRUG

20mg/day PRAX-628 for 6 weeks then 30mg/day PRAX-628 for remaining 6 weeks

Once daily oral

DRUG

Placebo

Once daily oral

Trial Locations (26)

10940

RECRUITING

Praxis Research Site, Middletown

18012

RECRUITING

Praxis Research Site, Granda

20817

RECRUITING

Praxis Research Site, Bethesda

28006

RECRUITING

Praxis Research Site, Madrid

28010

RECRUITING

Praxis Research Site, Madrid

28040

RECRUITING

Praxis Research Site, Madrid

29010

RECRUITING

Praxis Research Site, Málaga

32720

RECRUITING

Praxis Research Site, DeLand

33016

RECRUITING

Praxis Research Site, Miami Lakes

44718

RECRUITING

Praxis Research Site, Canton

46026

RECRUITING

Praxis Research Site, Valencia

60640

RECRUITING

Praxis Research Site, Chicago

63005

RECRUITING

Praxis Research Site, Chesterfield

65721

RECRUITING

Praxis Research Site, Ozark

70508

RECRUITING

Praxis Research Site, Lafayette

73112

RECRUITING

Praxis Research Site, Oklahoma City

75034

RECRUITING

Praxis Research Site, Frisco

77586

RECRUITING

Praxis Research Site, Seabrook

78681

RECRUITING

Praxis Research Site, Round Rock

79912

RECRUITING

Praxis Research Site, El Paso

85032

RECRUITING

Praxis Research Site, Phoenix

07601

RECRUITING

Praxis Research Site, Hackensack

08003

RECRUITING

Praxis Research Site, Barcelona

08035

RECRUITING

Praxis Research Site, Barcelona

08041

RECRUITING

Praxis Research Site, Barcelona

08222

RECRUITING

Praxis Research Site, Terrassa